胃癌患者血清TSGF和IAP测定的临床价值

目的探讨胃癌患者血清肿瘤标志物肿瘤特异性生长因子(TSGF)、免疫抑制酸性蛋白(IAP)测定在诊断及化疗疗效评价中的作用。方法用生化比色定量法及单向免疫扩散法分别测定46例胃癌、50例正常对照的TSGF、IAP值。结果 胃癌患者血清TSGF、IAP值较正常对照明显升高,且与胃癌诊断和化疗疗效密切相关。患者中有远处转移者TSGF、IAP测定值较未转移者明显升高。结论检测血清TSGF、IAP对胃癌的早期诊断、评定化疗疗效、监测复发、判断预后有重要的临床意义。     

恶性肿瘤患者血清TSGF测定及其临床意义

目的通过检测恶性肿瘤患者及比较其化疗前后血清TSGF水平,探讨TSGF 在恶性肿瘤诊断中的价值及与化疗疗效的关系.方法用TSGF试剂盒,以生化比色定量法测定血清TSGF值.结果恶性肿瘤患者血清TSGF水平较正常对照明显增高,且与恶性肿瘤诊断和化疗疗效密切相关.结论 TSGF值可作为诊断恶性肿瘤的重要标记物,并可评定化疗疗效.     

非小细胞肺癌患者血清胸腺嘧啶激酶定量测定的临床价值

目的 探讨非小细胞肺癌患者血清胸腺嘧啶激酶(TK)水平变化在化疗疗效及预后评估中的价值.方法 采用新型非放射性酶联免疫吸附试剂盒检测非小细胞肺癌患者血清TK水平.结果 化疗后非小细胞肺癌患者血清TK水平明显低于化疗前(P＜0.05).结论 非小细胞肺癌患者血清TK定量测定为非小细胞肺癌治疗的疗效评价和预后检测提供一个新的方法.     

血清CEA、CYFRA21-1及TSGF在肺癌化疗前后的表达变化及意义

目的 探讨血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和肿瘤特异性生长因子(TSGF)在肺癌化疗前后的水平变化及疗效评估价值.方法 选取80例接受紫杉醇联合吉西他滨化疗的肺癌患者,应用电化学发光免疫分析技术和生化比色法,检测化疗前及化疗21天后患者血清中CEA、CYFRA 21-1和TSGF水平变化.结果 患者血清中CEA、CYFRA 21-1和TSGF的水平在紫杉醇联合吉西他滨化疗后显著降低,差异具有统计学意义(P<0.05).且患者血清中CEA、CYFRA 21-1和TSGF水平变化与紫杉醇联合吉西他滨的化疗疗效具有明显的统计相关性.结论 肺癌患者应用紫杉醇联合吉西他滨化疗可明显降低血清CEA、CYFRA 21-1和TSGF水平,说明CEA、CYFRA 21-1和TSGF在临床肺癌治疗效果的评估中具有重要的意义.     

肿瘤坏死因子α在非小细胞肺癌患者中的临床价值探讨

目的　观察肿瘤坏死因子α(TNFα)在不同类型非小细胞肺癌患者的血清水平 ,并探讨TNFα与非小细胞肺癌患者的临床特征和临床疗效的关系。方法　以 40例非小细胞肺癌患者为研究组 ,2 0例正常健康者为对照组 ,用双抗体夹心ELISA法测定其血清水平。结果　非小细胞肺癌患者血清TNFα水平显著高于正常对照组 (P <0 .0 1 ) ,不同类型非小细胞肺癌间比较差异无显著性 ,但有远处转移者血清TNFα水平显著高于无远处转移者 (P <0 .0 5) ,化疗有效组血清TNFα水平较化疗前明显下降 (P <0 .0 5)。结论　非小细胞肺癌患者血清TNFα水平升高 ,且与病情的严重程度及化疗的临床疗效有关。本研究提示检测血清TNFα水平可用于判断非小细胞肺癌的病情和疗效评估     

NSCLC患者血清TIMP-1和TIMP-2检测的临床价值分析

目的:探讨血清金属蛋白酶组织抑制剂-1(TIMP-1)和金属蛋白酶组织抑制剂-2(TlMP-2)水平在晚期非小细胞肺癌(NSCLC)诊断及疗效预后评价中的临床价值.方法:用酶联免疫吸附法(ELISA)检测26名健康人和20例良性肺病患者及82例晚期NSCLC患者化疗前后血清TIMP-1、TIMP-2水平,并作对比分析.结果:NSCLC组化疗前血清中TIMP-1、TIMP-2水平均明显高于健康组(P＜0.01)和良性肺病组(P＜0.05).NSCLC患者化疗有效组在化疗结束后7 d的血清TIMP-1、TIMP-2水平明显低于化疗前,P＜0.01;化疗无效组化疗前、后血清TIMP-1、TIMP-2水平差异无统计学意义,P＞0.05.单因素生存分析提示,血清TIMP-1水平与晚期NSCLC患者的预后有关,P＜0.05.结论:NSCLC患者血清TIMP-1水平是一个有价值的肿瘤标志和预后指标,检测化疗前后血清TIMP-1、TIMP-2水平对评估化疗疗效有一定的临床意义.     

111. 肿瘤患者及其家族成员血清免疫抑制酸性蛋白的检测

近年来，血清免疫抑制酸性蛋白（IAP）作为恶性肿瘤的相关标志物已被应用于临床诊断、疗效分析及预后评估。而有关肿瘤易患人群的免疫状态及其与肿瘤遗传的相关性研究正引起人们新的关注，这方面的研究进展不仅有助于阐明肿瘤发生的机制，而且对预防和寻找癌前控制的途径皆具重要意义。本文应用单向免疫琼脂扩散法检测100例肿瘤患者（TP）（包括肺癌、乳腺癌、胃癌、大肠癌、肝癌等）和100例肿瘤家族成员（FM）的血清IAP水平，以评估IAP作为肿瘤易患人群筛选实际应用价值。结果发现100例肿瘤患者(TP)的血清IAP水平(803±188)与正常健康人(NS)的血清IAP水平(292±110)比较有明显差异(P＜0.01)，肿瘤家族成员组(FM)的血清IAP值（562±176）与正常健康人比较也有统计学差异（P＜0．01）。3组供血者的IAP阳性率（＞500 μg／mL）分别为82％（TP）、66％（FM）和5％(NS)。其中阳性率在80％以上的患者包括乳腺癌、肺癌、大肠癌和胃癌。IAP作为新近发现的一种肿瘤相关标志物，在正常生理条件下产生于巨噬细胞和肝细胞，属于人体血清和体液中的免疫抑制因子，在平衡免疫监护系统中起重要的负调节作用。本研究TP组的IAP值和阳性率显著高于NS组，表明IAP的检测可为肿瘤患者提供新的诊断方法。本文FM组的IAP值也显著高于NS组，则从细胞免疫学角度提示肿瘤家族成员作为肿瘤易患对象的客观存在。由于FM组仍具较高阳性率（66％），因此，我们认为IAP检测可被应用于肿瘤易患个体的筛选和随访，并为癌前期预防和监控提供又一新的途径。     

化疗与手术对肺癌患者血清endostatin水平影响的初步观察

目的:探讨肺癌患者化疗与手术前后血清内皮抑素(endostatin)水平的变化及临床意义。方法:用ELISA法检测20例良性肺部疾病患者和20例健康人及60例肺癌患者化疗和手术前后的血清endostatin水平,并作对比分析。结果:肺癌组血清endostatin水平明显高于良性肺部疾病组和健康人组(P<0.001),其水平与肿瘤大小有关,与组织学类型、临床分期无关。肺癌患者手术后7d血清endostatin水平明显低于手术前(P<0.001)。肺癌患者化疗受益组结束后3d血清内皮抑素水平明显高于化疗前和化疗结束后21d的水平(P<0.001)。结论:血清endostatin水平与肿瘤大小、手术及化疗有关。     

血清TPS、CEA、Pro-GRP和CYFRA21-1水平在肺癌患者中的临床意义

背景与目的血清肿瘤标志物在肺癌的诊断、疗效、预后判断中起着重要作用。本研究探讨血清组织多肽特异性抗原(tissue polypeptide specific antigen,TPS)与癌胚抗原(carcinoembryonic antigen,CEA)、胃泌素释放肽前体(precursor of gastrin-releasing peptide,Pro-GRP)和细胞角蛋白19片段(cytokeratin-19-fragments,CYFRA21-1)的水平及其在肺癌患者中的临床意义。方法应用ELISA检测82例肺癌患者化疗前及部分患者化疗后4种标志物水平。结果肺癌患者TPS、CEA、Pro-GRP阳性率及水平显著高于肺部良性疾病组和健康对照组。广泛期小细胞肺癌患者TPS阳性率显著高于局限期患者。患者化疗后TPS、CEA、Pro-GRP阳性率及水平均显著下降。非小细胞肺癌患者TPS水平是预后的独立因素。结论TPS在肺癌患者的辅助诊断、疗效观察有较好的临床意义,对非小细胞肺癌的预后判断方面可能有一定价值。     

血清p53抗体与肺癌生物学行为和化疗疗效的关系

目的通过对血清p53抗体与肺癌生物学行为和化疗疗效关系的研究,探讨血清p53抗体在肺癌中的临床意义。方法对57例初步诊断为肺癌的患者应用ELISA法检测血清p53抗体效价,经酶联免疫检测仪测吸光值E450,计算抗体指数,进行统计学分析。结果57例中阳性25例,阳性率为43.9%。血清p53抗体水平与肺癌的一般临床特征,如性别、吸烟指数无关,而与肺癌的病理类型、分期、分化和淋巴结转移有关。结论p53抗体的产生可能是肺癌发生的早期指征,是肺癌的不良预后因子,化疗前测定血清p53抗体可以预测化疗疗效。     

肺癌患者血清免疫抑制酸性蛋白检测

目的研究肺癌与血清免疫抑制酸性蛋白的关系。方法采用单向免疫扩散法,检测６５例肺癌患者、１５例肺部良性疾病病例、３０例健康对照人群血清免疫抑制酸性蛋白。结果肺癌患者血清免疫抑制酸性蛋白均值明显高于健康人和肺部良性疾患病人（Ｐ＜０．０５）。不同病理组织类型的肺癌之间、不同临床分期的肺癌患者之间,血清免疫抑制酸性蛋白水平无明显区别。结论免疫抑制酸性蛋白可作为肺癌的一个肿瘤标志物。     

Serum immunosuppressive acidic protein reflects systemic deterioration of colorectal cancer patient condition

AIMS: Immunosuppressive acidic protein (IAP) is a potent biological marker for immunological surveillance in patients with malignant tumors. This study aimed to investigate the significance of serum IAP as an index of disease status, clinicopathological findings and prognosis in colorectal cancer. METHODS: A total of 101 patients with colorectal cancer and 80 normal volunteers were included in this retrospective trial. Preoperative serum IAP was assayed using a commercially available enzyme-linked immunosorbent assay kit. RESULTS: The serum IAP level in the patients, which was not associated with clinicopathological features except for tumor size, was significantly higher than that in controls. The serum IAP level was closely correlated with percent body weight loss, serum albumin and cholinesterase, and percentage of circulating lymphocytes reflecting the host's nutritional and immunological conditions. Interestingly, these parameters were not associated with factors reflecting disease progression except for tumor size. The prognosis of patients with higher IAP levels was significantly worse than that of patients with lower IAP levels. Furthermore, an elevated serum IAP level was an independent prognostic marker in all patients. CONCLUSION: The preoperative serum IAP level may reflect the general condition of colorectal cancer patients, and thus may predict long-term survival independently of stage progression.     

An evaluation of carcinoembryonic antigen (CEA), beta 2-microglobulin (BMG), and immunosuppressive acidic protein (IAP) in the serum of primary lung cancer patients

The correlation between histological type and serum CEA, BMG, and IAP was studied in 98 patients with primary lung cancer. In particular, the results showed that the positive ratio in squamous cell carcinoma was increased by measuring serum BMG or IAP simultaneously with serum CEA more than by measuring serum CEA alone. Also, when these values were compared with histological type, adenocarcinoma showed an elevation of the serum CEA level, whereas squamous cell carcinoma showed an elevation of the serum BMG or IAP level. It was suggested that serum CEA, BMG and IAP levels were closely correlated with the histological type in primary lung cancer.     

肺癌化疗（VCR＋铂类）的急性期蛋白水平的变化

作者观察了２２例肺癌患者用ＶＣＲ＋ＤＤＰ或ＣＢＤＣＡ化疗前及化疗第３天和第５天血清ａ１－抗胰蛋白（ＡＡＴ）、触珠蛋白（ＨＰ）和转铁蛋白（Ｔｆ）等三项急性期蛋白的水平。结果表明，肺癌患者化疗前血清ＡＡＴ和Ｈｐ显著高于正常值（ｐ值分别小于０．０１和０．０５），血清Ｔｆ显著低于正常值（Ｐ＜０．０１）。化疗第３天和第５天时，化疗有效的９例患者其血清ＡＡＴ较化疗前显著升高（Ｐ＜０．０５），无效的１３例患者其血清ＡＡＴ尤明显变化。血清ＨＰ和Ｔｆ在化疗过程中无显著变化。化疗过程中血清ＡＡＴ浓度的升高率与化疗近期效果有关。结果提示，肺癌化疗过程中肿瘤组织的坏死可导致明显的急性期反应，且通过观察化疗初期血清ＡＡＴ升高率可估计肺癌对化疗的敏感性。     

Acute phase reaction during chemotherapy in small cell lung cancer

We have measured the serum concentration of the acute phase reactant, C-reactive protein (CRP), in 20 patients with histologically proven small cell lung cancer undergoing their first pulse of induction cytotoxic chemotherapy. Baseline CRP concentrations were raised in 16 of 20 patients (median baseline CRP 18.5 mg l-1; normal range less than 10 mg l-1). CRP levels more than doubled in 11 of 20 patients during induction chemotherapy. This acute phase reaction was seen in seven of the 10 chemosensitive patients, but was not observed in any of the five non-responding patients. Five patients were non-evaluable for chemoresponse. These data indicate that there is a previously undescribed quantifiable acute phase response during chemotherapy for small cell lung cancer which has potential for predicting chemoresponse.     

Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels

Summary Immunosuppressive acidic protein (IAP) has been described as a tumor marker in a number of malignant diseases. To evaluate the clinical importance of IAP in breast cancer patients, IAP serum level was determined in 75 breast cancer patients, using single radial immunodiffusion. Serum samples were also tested for CA 15-3. Cut off value for IAP was determined according to IAP serum level in 50 patients with benign, non inflammatory, diseases, and was set as 725 microgram/ml. Mean IAP serum level (623 mcg/ml) and positivity rate (20%) in 24 breast cancer patients with active disease were similar to those in 51 breast cancer patients with no evidence of disease (590 mcg/ml and 18%). The mean CA 15-3 serum level and positivity rate were significantly higher in patients with active disease (200 units/ml, 67%), compared to patients with no evidence of disease (18.3 units/ml, 6%). In our experience IAP was not found to be an effective tumor marker in breast cancer.     

Clinical investigation of serum immunosuppressive acidic protein (IAP) in patients with gastric cancer

Immunosuppressive acidic protein (IAP) is among the immunosuppressive factors so far detected in the blood of cancer patients. This study was undertaken to determine the blood level of IAP in patients with carcinoma of the gastrointestinal tract, particularly the stomach, and to define the clinical implications of IAP for the therapy. A close correlationship was established between the serum IAP level and the gross degree of malignancy of the tumor and clinical stage of disease, notably in patients with gastric cancer; the serum IAP level was increased with as the disease advanced, the increase being significant in the presence of metastasis or extensive spread of the lesion.     

大肠癌患者血清IAP、sIL-2R和IL-12变化

[目的]探讨检测血清IAP、sIL鄄2R和IL鄄12含量在大肠癌的辅助诊断、预后判断中的临床意义。[方法]采用单向免疫扩散法和ELISA法分别检测30例健康正常人及32例大肠癌患者手术前、后的血清IAP、sIL鄄2R和IL鄄12水平。[结果](1)大肠癌患者手术前血清IAP、sIL鄄2R水平均明显高于对照组(P<0.001和P<0.01),晚期组血清IAP、sIL鄄2R水平明显高于早期组(P<0.02和P<0.05),IAP与sIL鄄2R水平呈显著正相关(r=0.987,P<0.001);大肠癌患者血清IL鄄12水平明显低于对照组(P<0.05)。(2)串联IAP、sIL鄄2R两指标筛检大肠癌的敏感性为78.1%,特异性为93.33%,并联两指标筛检大肠癌,其敏感性为93.75%,特异性为73.3%。(3)手术后患者血清IAP、sIL鄄2R水平均明显低于手术前(P<0.001),早期组下降有明显差异性(P<0.001),而晚期组下降不明显(P>0.1);患者术后血清IL鄄12水平明显比术前升高(P<0.02),早期组上升显著(P<0.001),晚期组上升不明显(P>0.05)。[结论](1)检测患者血清IAP、sIL鄄2R水平对大肠癌的辅助诊断、病情判断、手术治疗和预后观察均有较高的临床价值。(2)联合检测血清IAP、sIL鄄2R对筛检大肠癌患者具有较高的敏感性。(3)血清IAP、sIL鄄2R和IL鄄12可作为指导大肠癌患者免疫学治疗较客观的指标。